Formosa Pharmaceuticals, Inc. (TPE:6838)

Market Cap	5.53B
Revenue (ttm)	16.15M
Net Income (ttm)	-222.29M
Shares Out	150.98M
EPS (ttm)	-1.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,439,778
Average Volume	2,980,667
Open	36.00
Previous Close	34.15
Day's Range	33.85 - 36.90
52-Week Range	21.55 - 58.20
Beta	1.05
RSI	73.80
Earnings Date	Aug 11, 2025

About Formosa Pharmaceuticals

Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007 that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-0110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian g...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6838

Financial Performance

In 2024, Formosa Pharmaceuticals's revenue was 143.36 million, an increase of 359.89% compared to the previous year's 31.17 million. Losses were -201.01 million, -37.56% less than in 2023.